Form 4: ALX Oncology CEO Sells Shares for Tax Obligations

ALX Oncology Holdings Inc. CEO Jason Lettmann disposed of 2,201 shares of common stock to cover tax liabilities related to RSU vesting.

Summary

• Jason Lettmann, Chief Executive Officer and Director of ALX Oncology Holdings Inc. (ALXO), reported a transaction on February 17, 2026.
• 2,201 shares of ALXO common stock were disposed of at a price of $2.27 per share.
• The disposal was a 'F' transaction code, indicating shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units (RSUs).
• Following this transaction, Mr. Lettmann beneficially owns 305,920 shares of common stock.
• The total beneficial ownership includes 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction primarily driven by tax obligations related to RSU vesting, which is a neutral event, slightly offset by the positive signal of ESPP participation.

Positives

• Inclusion of 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2025, indicates continued participation in company equity programs.

Negatives

• Disposal of 2,201 shares of common stock, reducing direct beneficial ownership, even if for tax purposes.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to tax obligations from restricted stock unit (RSU) vesting, are common and generally not indicative of a change in management's long-term view of the company, unlike open market sales. The inclusion of shares acquired via an Employee Stock Purchase Plan (ESPP) further suggests routine equity participation.

Stakeholder Impact

• Shareholders: The transaction represents a minor reduction in direct beneficial ownership by the CEO due to tax withholding, which is a routine event and generally has minimal impact on overall shareholder value or perception. The CEO's overall beneficial ownership remains substantial.

Key Dates

Recommendation

This Form 4 reports a routine transaction where the CEO disposed of a small portion of shares to cover tax liabilities from RSU vesting, a common practice. It also notes an acquisition via an ESPP. These actions do not provide a strong signal for a change in investment thesis, suggesting a 'hold' recommendation.

Keywords

ALX Oncology, ALXO, Jason Lettmann, Form 4, Insider Transaction, Stock Sale, RSU, Tax Withholding, CEO